Cerulean Pharma (CERU) Tops Q2 EPS by 6c

Cerulean Pharma (NASDAQ: CERU) reported Q2 EPS of ($0.37), $0.06 better than the analyst estimate of ($0.43).

For earnings history and earnings-related data on Cerulean Pharma (CERU) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Cisco rating cut at HSBC as analyst sees a lack of catalysts
• Neumora Therapeutics, Inc. (NMRA) Tops Q2 EPS by 4c